WO2024180207 - PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
National phase entry is expected:
Publication Number
WO/2024/180207
Publication Date
06.09.2024
International Application No.
PCT/EP2024/055318
International Filing Date
01.03.2024
Title **
[English]
PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
[French]
DÉRIVÉS DE PYRIDAZINYL AMINO UTILISÉS EN TANT QU'INHIBITEURS D'ALK 5
Applicants **
CHIESI FARMACEUTICI S.P.A.
Via Palermo 26/A
43122 Parma, IT
Inventors
PIZZIRANI, Daniela
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
RONCHI, Paolo
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
TARSI, Luca
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
Priority Data
23159709.7
02.03.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 967 | |
| EPO | Filing, Examination | 4727 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2635 |
Total: 9435 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention generally relates to compounds inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof; the compounds of the invention may be useful for instance in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.[French]
La présente invention concerne de manière générale des composés inhibant le récepteur du facteur de croissance transformant β (TGFβ) de type I (ALK5) (ci-après, inhibiteurs d'ALK5), des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique ; les composés de l'invention peuvent être utiles par exemple dans le traitement de maladies, troubles ou états nombreux associés à la voie de signalisation ALK5.